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The aim of this study was to investigate the effectiveness of Photodynamic Therapy (PDT) using
Methylene Blue (MB) as the photosensitizing compound and a Light-Emitting Diode (LED) in American
cutaneous leishmaniasis (ACL). Hamsters were experimentally infected with Leishmania (Leishmania)
amazonensis. After the development of the lesions in the footpad, the animals were treated with MB three
times a week for 3 months. Ten minutes after each application of MB, the lesions were irradiated with
LED for 1 h. The lesions were evaluated weekly by the measurement of the hamster footpad thickness.
At the end of the treatment the parasitic load was quantiﬁed in the regional lymph node of the hamsters.
The treatment promoted a decrease in the thickness of infected footpad (P = 0.0001) and reduction in the
parasitic load in the regional lymph node (P = 0.0007) of the animals from group treated with MB + LED.
PDT using MB + LED in ACL caused by L. amazonensis shows a strong photodynamic effect. This therapy is
very promising, once it is an inexpensive system and the own patient can apply it in their wound and in
their house without the need of technical assistance.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Leishmaniasis, is one of commonest parasitic diseases in the
world and according to the World Health Organization more than
12 million people in 88 countries are infected and around 350 mil-
lion people are at risk (WHO, 2009). The annual incidence is esti-
mated as 1–1.5 million cases of cutaneous leishmaniasis and
500,000 cases of the visceral form (WHO, 2009).
Cutaneous leishmaniasis (CL) is characterized by single or
multiple lesions in the skin or in the mucosa tissues which develop
into oral, nasal and pharyngeal destruction (Neves et al., 2000).
American cutaneous leishmaniasis (ACL) is caused by Leishmania
of the subgenus Leishmania and Viannia, the most common being
Leishmania braziliensis, Leishmania guyanensis, Leishmania panam-
ensis, and Leishmania amazonensis (Neves et al., 2000).Análises Clínicas e Biomed-
Colombo, 5790, 87.020-900,
).
evier OA license.The treatment of leishmaniasis is based, mainly, on injection of
pentavalent antimony derivatives, as ﬁrst choice, and also ampho-
tericin B, paromomycin and pentamidine isothionate (Brazil,
2007). Because the high incidence of collateral effects (arthralgia,
myalgia, anorexia, nausea, vomiting, swelling and local pain) and
the discomfort of daily injections, patients tend to interrupt
treatment and the disease may evolve with serious complications
and may develop drug resistance (Brazil, 2007). Therefore, applica-
tion of a topical formulation is seen as more desirable than local
injections or systemic therapy, resulting in better treatment
compliance.
Photodynamic Therapy (PDT), using a photosensitizing com-
pound (PS) and visible light producing reactive oxygen species
(Macdonald and Dougherty, 2001; Mang, 2004), has been success-
fully applied for treatment of local and topical diseases such as
macular degeneration, skin lesions and cancer (Levy, 1995;
Machado, 2000; Sternberg and Dolphin, 1996; Sternberg et al.,
1998; Gollnick et al., 2003) and Leishmania eradication with low
scar formation (Akilov et al., 2007a; van der Snoek et al., 2008).
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2006), cationic and anionic PS (Akilov et al., 2006), aminolevulinic
acid (ALA) and protoporphyrin IX (Akilov et al., 2007b), and two
cationic PS (Akilov et al., 2007a) have produced encouraging re-
sults in Leishmania treatement. All were tested against Leishmania
major and to a lesser extent Leishmania donovani and Leishmania
tropica (Gardlo et al., 2003; Enk et al., 2003; Asilian and Davami,
2006; Ghaffarifar et al., 2006; Sohl et al., 2007) which are more
common in Europe.
Few PDT studies have been carried out against Leishmania spe-
cies causing ACL and we could only ﬁnd reports of phthalocyanine
derivatives used against L. amazonensis (Dutta et al., 2005), L.
panamensis and Leishmania chagasi (Escobar et al., 2006). As ACL
are endemic diseases in forest areas and, usually, the native popu-
lation from these areas cannot afford expensive treatments, low
cost treatments are desirable and may help to control this disease.
Additionally, it is well known that the combination of Methylene
Blue (MB) and different light sources such as Light-Emitting-
Diodes (LED) or low potency lasers are effective against prokaryote
and eukaryote cells (Tardivo et al., 2004; Tardivo et al., 2005;
Wainwright et al., 1997; Zeina et al., 2001; Floyd et al., 2004;
Huang et al., 2004; O´Riordan et al., 2005; Peloi et al., 2008).
However there are no reports of effectiveness of this combination
against Leishmania species. Therefore, the aim of our study was
to investigate the photodynamic effectiveness of MB and Light-
Emitting Diode (LED) against ACL in hamsters experimentally
infected with Leishmania (L.) amazonensis.2. Materials and methods
2.1. Chemical and LED device
Methylene Blue (MB, Vetec, C16H18ClN3S3H2O, MW
373.90 g mol1) and all other chemicals were analytical grade
and were used without puriﬁcation. The LED (EverLight Co.) light
systemwas constructed using 6 units (in series) that emit red light,
and their individual output was determined using a Handheld La-
ser Power Meter (Edmund Optics Inc.). The LED emission (maxi-
mum at 663 nm) and MB absorption (maximum at 665 nm)
spectra were recorded in a SPEX Fluorolog2 model 1680 and in a
Varian Cary 50 spectrophotometer, respectively.
2.2. Parasite
Leishmania (L.) amazonensis (MHOM/BR/73/M2269) was iso-
lated from experimentally infected hamsters and cultured in
medium 199 supplemented with 10% of fetal calf serum, 20 mM
L-glutamine, 1% human urine and antibiotics (100 UI/mL penicillin
G and 100 lg/mL streptomycin) at 26 C, by weekly passages.
2.3. Experimental infection
Thirty-eight male golden hamsters (90 days old) from the
Animal Laboratory of Universidade Estadual Paulista (UNESP, Assis
– SP, Brazil) were intradermically inoculated with 100 lL of
physiological saline (PS) containing 5  106 promastigote forms
of L. amazonensis in the posterior right footpad. The posterior left
footpad, inoculated with 100 lL of uninfected PS was used as a
vehicle control. The development of the lesions in the footpads
were observed and measured for up to 12 weeks.
2.4. Photodynamic Therapy of MB/LED-PDT
The animals were separated in three groups: Control group
(n = 8) treated with MB half in lotion and half in water withoutLED, group A (n = 14) treated with oil/water (O/W) lotion with
10 nM MB and group B (n = 15) treated with 10 nM MB aqueous
solution (15 animals), and treatment started 90 days after infec-
tion. Before each treatment, the animals were anaesthetized with
a combination of xylazine (10 mg/kg – Rompum) and ketamine
chlorohydrate of (50 mg/kg – Ketamina). The footpad of the in-
fected animals were treated with MB three times a week for
3 months. 10 min after the each application of MB, LED (665 nm,
5 mW cm2) was used for 1 h (12 J cm2). The control group re-
ceived only MB without any irradiation.2.5. The evaluation of lesions
The lesions were evaluated weekly by measurement of footpad
thickness using a dial thickness gauge (Mitutoyo, Japan). The le-
sion thickness was expressed as the difference between the in-
fected footpad and the contralateral uninfected footpad.2.6. Quantiﬁcation of parasites in lymph node and spleen
Parasites were quantiﬁed in the lymph node and spleen of the
hamsters after the end of the treatment, following the method de-
scribed by Buffet et al. (1995), with slight modiﬁcations. The ani-
mals were euthanized under deep anesthesia. From each animal
the popliteal lymph node and the spleen were aseptically removed
and weighed. Each organ was macerated and the suspension was
passed through a needle (insulin type) several times to disrupt
the cells. The suspensions were diluted 1:4 and transferred to
96-well plates containing medium 199 (Gibco, Invitrogen Corpora-
tion) and incubated at 26 C for 30 days. Next, each well was exam-
ined in an inverted light microscope searching for promastigote
forms and the titer was considered as the highest dilution where
least one parasite could be found. The incubation was extended
for a further 15 days and re-examined. The parasitic load in each
organ was calculated as geometric mean of the titers multiplied
by 16.7 and divided by the total mass of the organs (in grams),
where 16.7 represents the fraction of the suspension of each organ
inoculated in the ﬁrst well of the culture plate.2.7. Statistical analysis
All results were analyzed by Shapiro Wilk’s normality tests fol-
lowed by Student’ t test using the StatSoft software; signiﬁcant
differences were considered at the 5% level.2.8. Ethical aspects
All procedures were performed according to protocols approved
by the Committee on Research Animal Care of the State University
of Maringá (report 028/2006 on 11/Jul/2006).3. Results
The development of the lesions in experimentally infected ham-
ster were measured weekly for 12 weeks. After this, the hamster
footpads were treated with 10 nM MB dissolved in lotion (group
A) or water (group B) and irradiated with LED for 1 h three times
a week for 12 more weeks (Fig. 1).
The control group treated with MB in lotion or water without
LED irradiation, presented a continuous increase in thickness
throughout the treatment, showing that MB alone was not able
to prevent the development of lesions. In contrast, the thickness
of the footpad in the groups treated with MB + LED was signiﬁ-
cantly decreased (P = 0.0001; P = 0.0001), indicating a strong
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Fig. 1. Effect of MB/LED-PDT on lesions of hamsters infected with Leishmania (L.)
amazonensis. The thickness of the footpad of hamsters infected with 5x106
promastigotes of Leishmania (L.) amazonensis was measured weekly for 12 weeks
until lesion development and the treatment with MB or MB + LED started and
followed weekly for 12 more weeks. The lesion was evaluated by the difference
between the thickness of footpad and its contralateral footpad. Half of the control
group was treated with MB in lotion and half MB in water (n = 8) and group A
(n = 14) were treated with MB in lotion and group B (n = 15) received MB in water.
The values represent mean ± SD of the total number of animals of the each group.
P < 0.001 compared to control group.
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Fig. 3. Effect of MB/LED-PDT on parasite load in hamsters infected with Leishmania
(L.) amazonensis. Hamsters were infected with 5106 promastigotes forms of
Leishmania (L.) amazonensis and treated with MB/LED-PDT. Control group (n = 8)
was treated with MB but was not irradiated with LED. After the treatment for
12 weeks, the parasite load in the popliteal lymph node of infected footpad was
evaluated. ⁄P < 0.05 compared to control group.
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groups A or B (P = 0.470).
The morphology of the lesions was also evaluated. Before
MB + LED treatment, all animals had lesions in the infected footpad
and more than 40% of them had ulcerated lesions. After 6 weeks of
treatment with MB + LED, only 13.3% of the animals in group B and
none in group A, had ulcerative lesions. At the end of treatment
(12 weeks) 40% and 50% of the lesions in animals in groups A
and B, respectively, were completely healed, while all animals in
the control group, treated with MB only, had ulcerative lesions.
Fig. 2 shows a sequence of photographs of the infected footpad
treated with the combination of MB + LED during and after
12 weeks of treatment, where re-epitelization, regression and heal-
ing can be seen.
The parasitic load in the spleen and in the popliteal lymph node
of the infected hamsters was also investigated (Fig 3). No parasites
were found in the spleens of any treated animal showing that the
parasites did not migrate into spleen in the animals treated with
MB + LED. In the popliteal lymph node, parasites were found in
87.5% of the control animals, while in the groups treated with
MB + LED the percentage was smaller (28.6% for group A andFig. 2. Development of the lesion in hamster infected with Leishmania (L.)
amazonensis and treated with MB/LED-PDT. Hamsters were infected with 5  106
promastigotes forms of Leishmania (L.) amazonensis and after the development of
the lesion, the animals were treated with MB/LED-PDT. (A) Before treatment
(90 days of infection); (B) After 6th weeks of treatment; (C) After 12 weeks of
treatment.13.3% for group B). The parasite load in the groups treated with
MB + LED was smaller compared to the control group (P = 0.0007
for group A and P = 0.0001 for group B). There was no signiﬁcant
difference in the parasitic load between groups A and B (P = 0.53)
showing that MB in either water or O/W did not interfere in the
permeability of MB into parasite membrane.4. Discussion
Little effort has been made to improve the treatment of leish-
maniasis around the world and the medicines recommended for
treatment have been used for more than 90 years (Rath et al.,
2003). Despite the high incidence of side effects and discomfort
for the patient from daily subcutaneous injection, the pentavalent
antimonials remain the ﬁrst choice for treatment (Brazil, 2007;
Rath et al., 2003). New therapies which ally lower costs, lower side
effects and higher efﬁciency are urgently needed.
PDT has produced some success in treating superﬁcial dis-
easesLevy, 1995; Machado, 2000; Sternberg and Dolphin, 1996;
van der Snoek et al., 2008) and the approval of protoporphyrin
has fueled the search for new photosensitizers (Machado, 2000;
Sternberg et al., 1998; van der Snoek et al., 2008).
Several reports have demonstrated the efﬁcacy of PDT for Old
World CL using different photosensitizers. Among them, Gardlo
et al. (2003) had treated ﬁve cases of CL with PDT using Metvix
(Photocure, Oslo, Norway), 75 J cm2 of red light, applied twice a
week, during 12 weeks followed by application once a week for a
further 4 weeks. All patients involved in the study were healed,
with excellent cosmetic results and the lesions were clinically
and histologically free of parasites with no recurrence throughout
the observation time (10 months). Enk et al. (2003) treated 32 le-
sions in 11 patients, of whom 10 had lesions healed after two
PDT applications. Another study (Asilian and Davami, 2006),
involving 20 patients with 31 lesions, was carried out with amino-
levulinic acid (ALA-PDT), 100 J cm2, once a week, for 4 weeks. The
results were satisfactory with 29 lesions completely healed and the
other two being partially cure.
The main limitation to widespread use of PDT is the price of
the PS and the light source, since leishmaniasis is mainly found
in undeveloped countries where expensive treatments are unaf-
fordable. MB is an inexpensive dye and has been shown to be a
good PS for PDT (Peloi et al., 2008) and the combination of
MB + LED was successful in our study in treating lesions caused
by L. amazonensis in experimentally infected hamsters. After
12 weeks, half of the treated animals had their lesion healed
356 L.S. Peloi et al. / Experimental Parasitology 128 (2011) 353–356and, from visual analysis, the appearance of the lesions was better
and the tissue around the lesions was undamaged. Furthermore,
no parasites were found in the popliteal lymph node in more than
79.3% of the treated animals and the mean parasitic load was
smaller in treated animals than in control animals.
Studies carried out with animals infected with L. major and trea-
ted topically with ALA-PDT or PPA904-PDT also had a signiﬁcant
reduction in the parasitic load, although local tissue damage was
still observed (Akilov et al., 2007b).
Clinical cure of human patients is considered when the lesions
are completed healed (Brazil, 2007). Despite results that showed
clinical cure, this was not associated with the clearance of para-
sites, this being a hallmark of leishmaniasis. It is known that a
low number of viable organisms still persist within lymphoid tis-
sue and/or in the site of the former skin lesion after selfcure or suc-
cessful chemotherapy (Ramírez and Guevara, 1997) and the
clinical cure does not always coincide with histopathologic cure
(Mendonça et al., 2004). It is possible that healing/cure depends
on both the immune response of the host and on genotypic and
phenotypic features of the parasite and play a role in the persis-
tence of parasites (Mendonça et al., 2004).
Special and expensive equipment and time-consuming proce-
dures have been emphasised as disadvantages of PDT treatment
(van der Snoek et al., 2008), but the system used for this study is
simple and cheap. The LED device is inexpensive, easy to handle
and to transport, a MB is available in any local market and treat-
ment can be carried out in the patient´s house without any special
technical training.
5. Conclusions
PDT with MB + LED, a very inexpensive system, promoted sig-
niﬁcant reduction in the size of the lesion, in the parasitic load in
the draining lymph node and healed the lesions in hamsters exper-
imentally infected with L. amazonensis. Although the MB/LED-PDT
provided promising results, further studies are necessary to better
understand its mechanism of action and assure the safety and efﬁ-
cacy for use in humans.
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